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Abstract
Plasma prekallikrein (PPK) is synthesised in hepatocytes
and secreted into the blood, where it participates in the
surface-dependent activation of blood coagulation,
fibrinolysis, kinin generation and inflammation. Recently
we demonstrated by quantitative RT-PCR that the human
PPK gene is transcribed not only in the liver, but also in
various non-hepatic human tissues at significant levels.
However, up to now no reliable information is available
concerning protein synthesis in the corresponding
human tissues. Here we demonstrate by immunohisto-
chemical studies that PPK or plasma kallikrein (PK) is
localised in cells of different embryologically derived
human tissues. In the human nephron, single cells of the
distal tubules stained intensely, while the cytoplasm of
cells forming proximal tubules and collecting ducts
stained uniformly. PPK/PK was localised in hepatic epi-
thelial cells of the liver, in cells of the pancreatic islet of
Langerhans, in the interstitial Leydig cells of the testes,
in the follicular and thecal granulosa cells of the ovary,
and in the parotid gland, oesophagus, skin, respiratory
tract, prostate and breast. We conclude that the cellular
localisation of PPK/PK in multiple different progenitor-
derived cells indicates specific cellular functions of this
enzyme, in addition to its known function in the blood.
Keywords: cellular functions of plasma prekallikrein;
kidney; KLKB1; pancreas; plasma kallikrein; plasma
prekallikrein.
Introduction
Plasma and tissue kallikreins belong to the family of ser-
ine proteases to which several important physiological
functions have been ascribed. Of these, the notable func-
tions are modulation of cardiovascular dynamics, acti-
vation of complement and the initiation of inflammatory
responses (Bhoola et al., 1992). The primary protease
action of the two kallikreins is the formation of the vaso-
active kinin peptides from endogenous multifunctional
protein substrates termed kininogens.
The focus of this study is plasma prekallikrein (PPK),
the zymogen of plasma kallikrein (PK), which is a single-
chain glycoprotein that is synthesised in hepatocytes and
secreted into the blood, where it forms a complex with
its endogenous substrate, high-molecular-weight kini-
nogen (Bhoola et al., 1992). PPK is encoded by a single
gene (KLKB1) of approximately 31 kb in length that is
located on chromosome 4q34–35 and is structurally
similar to the thromboplastin antecedent factor (factor XI)
gene (Asakai et al., 1987). The gene consists of 15 exons,
the first two exons encoding the 59-untranslated region
and the signal peptide, the next eight the heavy chain,
and the last five exons the light chain representing the
protease segment of the molecule (accession no.
AF232734-42).
Recent studies by quantitative RT-PCR demonstrated
that the PPK gene is transcribed not only in the liver, but
also at significant levels in non-hepatic human tissues
(Figure 1, from Neth et al., 2001). Here we examined the
question as to whether PPK mRNA in extrahepatic tis-
sues is actually translated into the zymogen protein. We
used an immunohistochemical approach to immunolabel
PPK/PK in different embryologically derived human tis-
sues primarily of metanephric/mesenchyme, ectodermal/
endodermal and endocrine/neural crest lineage, and
localised PPK/PK to cells of all tissues investigated. The
cellular delineation of PPK/PK in different progenitor
derived cells indicates specific cellular functions of plas-
ma kallikrein, in addition to its known function in the
blood.
Results
Cross-reactivity of PPK/PK antibodies with human
IgG
During the validation of an antibody to human PPK for
use in immunohistochemical studies, we noted strong
cross-reactivity with human IgG (cf. materials and meth-
ods). The reason for this cross-reactivity is obviously due
to the fact that, depending on the isolation procedure,
preparations of human PPK may contain IgG as a minor
contaminant (Gallimore et al., 1978). Since IgG acts as
an excellent antigen, even spurious amounts of IgG, such
as present in commercially available PPK, will give rise
to the generation of antibodies. To prevent cross-reacti-
vity with IgG in our immunohistochemical studies, we
removed antibodies to IgG by affinity chromatography on
IgG-Sepharose. In two recent publications warising from
a project proposal by EF and KDB on PK/PPK (Volks-
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Figure 1 Expression of plasma prekallikrein mRNA in human
tissues.
The expression of PPK mRNA in non-hepatic tissues is shown
as a percentage of expression in liver (Figure modified and
reproduced with permission from Neth et al., 2001).
wagen Foundation Grant) with a collaborating groupx on
the immunolocalisation of PPK/PK in human blood ves-
sels (Cerf et al., 1999) and in human brain (Cerf and Rai-
doo, 2000), the antibodies used had been raised against
commercially available PPK and had not been validated
with respect to cross-reactivity with human IgG; there-
fore, these data have to be interpreted with caution.
We also observed cross-reactivity with IgG for the PK-
specific antibody (U691.10) raised against a peptide anti-
gen, but in this case the IgG cross-reactivity (approx.
one-fifth compared to PK) was obviously due to
sequence similarity of the peptide antigen with sequence
motifs of IgG heavy chains (cf. materials and methods).
To investigate whether any of the antibodies used for
PK/PPK localisation also detected IgG in human tissue,
we compared their immunoreactivity to PPK/PK with that
to a commercial antibody to human IgG on human kidney
sections. While antibodies to PPK/PK showed clear cel-
lular localisation in various portions of human nephron,
the antibody to human IgG detected immunoreactivity
only in the renal interstitium and lumen of blood vessels,
including glomerular capillaries (not shown).
Plasma kallikrein-specific antibody
With the aim of discriminating PK and PPK in tissue sec-
tions, an antibody was raised against a peptide that rep-
resents the C-terminal end of the heavy chain of PK,
which is newly formed upon activation of PPK by cleav-
age of the Arg371-Ile372 peptide bond. Therefore, antibod-
ies against this peptide should be specific for active PK.
Western blot experiments revealed that the sensitivity of
antibody U691.10 for PK is at least ten-fold higher than
for PPK, since 0.3 mg of PK gave a very intense signal,
whereas 2 mg of PPK resulted in a barely visible band
(data not shown). However, positive staining obtained
with this antibody in immunolocalisation studies was
identical to that for the other four antibodies that detect
both PK and PPK. Therefore, we assume that the PK
detected by this PK-specific antibody is due to activation
of PPK during tissue processing.
Visualisation of immunolabelled human PPK/PK in
human tissues
Kidney Kidney exhibited the third highest PPK mRNA
expression (24.5% compared to liver; Neth et al., 2001)
and therefore significant positive immunostaining for PK/
PPK was expected. In the current study we observed
intense staining of PPK/PK in cells of the proximal
tubules (Figure 2C,D), distal tubules and collecting ducts
(Figure 2E). Staining was also observed in epithelial cells
of Bowman’s capsule (Figure 2B). All of these cells were
uniformly stained, whereas in distal tubules a similar
intensity of immunolabelling was visualised only in single
cells identified as connecting tubule cells after perform-
ing double staining techniques (PPK/PK and tissue kal-
likrein, hK1; data not shown). Cellular visualisation of
PPK/PK with the five antibodies (see methods) was
essentially similar. Interestingly, immunoreactivity was
occasionally observed in nuclei and the nuclear envelope
of some tubular cells (Figure 2D). Controls in which the
anti-PPK/PK antiserum was replaced by non-immune
serum or preabsorbed with excess antigen showed no
immunostaining (Figure 2F).
Liver Although hepatocytes were considered to syn-
thesise plasma prekallikrein and PPK mRNA expression
was highest in the liver (Neth et al., 2001), direct evidence
of its presence in the liver was obtained only when the
enzyme was demonstrated in isolated hepatocytes by
immunofluorescence (Henderson et al., 1992). In the cur-
rent study, we confirmed the localisation of PPK/PK in
human hepatocytes (Figure 3A). It is therefore assumed
that following synthesis, PPK is secreted together with
H-kininogen into the liver sinusoids. Immunostaining was
intense in some cells, while others were faintly stained
(Figure 3A).
Oesophagus and skin Staining was concentrated in
the squamous epithelium of oesophagus and epidermis
(Figure 3B,F). Again the immunoreactive protein was
intensely expressed in the nuclei of numerous epithelial
cells forming the squamous epithelium of the oesopha-
gus and epidermis.
Parotid gland Immunoreactive PPK/PK was observed
in acinar cells of the parotid gland. Staining was more
intense on the apical cell membrane of acinar cells, sug-
gesting a cell membrane distribution of the enzyme (Fig-
ure 3E).
Stomach In the stomach, PPK/PK staining appeared
to be confined to the parietal cells of the gastric mucosa,
whose major function is the secretion of hydrochloric
acid (data not shown).
Respiratory tract With 0.3% compared to liver,
mRNA expression in lung was very low (Neth et al.,
2001). Nevertheless, as in the epithelium of other glan-
dular organs, epithelial cells forming the respiratory epi-
thelium stained positively for PPK/PK. The respiratory
epithelium stained with similar intensity at different levels
of the respiratory tree, namely trachea, bronchi and bron-
chioles (Figure 3C,D). Staining of nuclei of epithelial cells
was also observed with variable strength. Goblet cells
did not appear to express immunoreactive PPK/PK.
Prostate and breast These glandular organs ex-
pressed immunoreactivity for PPK/PK in epithelial cells
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Figure 2 Immunolocalisation of PPK/PK in human kidney.
Immunoreactivity is associated with tubular segments of the human nephron (A), including proximal tubules (C, D) and medullary
collecting ducts (E). Immunostaining is also observed in epithelial (parietal) cells (arrows) of Bowman’s capsule (B) and in some nuclei
of proximal tubule cells (D, solid arrows) while others remain unstained (D, broken arrow). Replacement of anti-PPK/PK antibody by
non-immune serum resulted in the absence of staining (F). G, glomerulus. Scale bars: (A,E) 200 mm; (B,D) 25 mm; (C,F) 50 mm.
forming both ducts and acini, but the staining intensity
was stronger in ducts than in the acini of human breast
(Figure 3G,H).
Pancreas We visualised intense specific staining for
PPK/PK in endocrine cells forming the islets of Langer-
hans. The exocrine portion of the gland did not express
significant immunoreactivity compared to the endocrine
portion (Figure 4A,B). In accordance with the pattern of
staining observed in the islets, it seems highly likely that
immunoreactive PPK/PK is expressed in insulin-secreting
cells. PPK mRNA expression in pancreas (Neth et al.,
2001) was 68% of that in liver, which may indicate a high
level of transcription in the islets of Langerhans, since the
islets represent only ;1–2% of the mass of pancreatic
tissue.
Ovary In the ovary, follicular granulosa cells showed
immunostaining for PPK/PK (Figure 4C,D), which begins
to disappear in the atresic follicles after luteinisation. Our
previous analyses showed that PPK mRNA expression in
ovary was low, at approximately 0.6% of the value for
liver (Neth et al., 2001).
Testes Intense staining for PPK/PK was visualised in
Leydig cells (Figure 4E,F). Other components of the
organ, such as the seminiferous tubules, were free of
detectable staining (Figure 4E). Relative to the expression
of PPK mRNA in liver, the value for testes was approxi-
mately 10% (Neth et al., 2001). Immunoreactivity of the
nuclear envelope of Leydig cells was also a characteristic
observation (Figure 4F).
Discussion
Early experiments focused on a critical analysis of the
molecular steps that control the participation of PPK in
contact activation, regulatory control of vascular tone,
fibrinolysis and initiation of the inflammation cascade.
Subsequent in vitro studies examined the contact acti-
vation events that lead to the conversion of PPK to active
PK. This molecular step was achieved by cleavage of the
peptide bond Arg371-Ile372, either in the fluid phase by fac-
tor XII fragment (bFXIIa) or on a negatively charged
surface by activated factor XII (FXIIa) with high-molecu-
lar-weight kininogen as cofactor (contact activation).
FXIIa-independent PPK activation has been shown to
take place on the surface of endothelial cells: PPK,
assembled on endothelial cell surface-bound high-
molecular-weight kininogen as a multiprotein complex
that comprises cytokeratin 1, gClqR and plasminogen
activator receptor, is activated in the absence of FXIIa by
a protease (Colman and Schmaier, 1997; Motta et al.,
1998, 2001) which has been identified as prolylcarboxy-
peptidase (Shariat-Madar et al., 2002). In addition, it
has been evidenced that activation of prekallikrein
complexed to kininogen on the endothelial cell surface
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Figure 3 Immunoperoxidase labelling of PPK/PK in human liver (A), oesophagus (B), lung (C, D), parotid gland (E), skin (F), prostate
(G) and breast (H).
Arrows indicate nuclear localisation of the enzyme in epithelial cells of oesophagus (B), respiratory tract (D) and epidermis (F). BV,
blood vessels; L, lumen; SA, serous acinus; MA, mucous acinus. Scale bars: (A,G) 40 mm; (C,H) 200 mm; (E) 30 mm; (B,D,F) 50 mm.
can be catalysed by heat shock protein 90 by an as yet
unidentified mechanism (Joseph et al., 2002).
The protease activity of PK is also involved in the acti-
vation of circulating neutrophils (Schapira et al., 1982,
1983; Wachtfogel et al., 1983); it efficiently converts pro-
urokinase plasminogen activator, thereby inducing the
fibrinolytic cascade (Ichinose et al., 1986; Hauert et al.,
1989). A major function of PK is the release from high-
molecular-weight kininogen of the nonapeptide brady-
kinin, which through its specific receptor-coupling of
second messengers regulates cellular events (Bhoola et
al., 1992; Blais et al., 2000). Whether or not PPK, togeth-
er with FXII and high-molecular-weight kininogen, con-
tributes to haemostasis is at present questionable
(Colman and Schmaier, 1997; Schmaier, 1998).
For some time the synthesis and cellular localisation of
PPK was regarded as residing exclusively in the hepa-
tocyte, which secretes the pre-protease PPK and its
co-factor high-molecular-weight kininogen into the cir-
culation. The molecules circulate as a complex either free
or attached to the external surface of neutrophils (Scha-
pira et al., 1982; Henderson et al., 1994). Experimental
evidence gathered from RT-PCR studies clearly suggest-
ed PPK mRNA expression in several extra-hepatic tis-
sues (Ciechanowicz et al., 1993; Hermann et al., 1996,
1999). Recently we confirmed and extended these stud-
ies and demonstrated by quantitative RT-PCR the
expression of PPK mRNA in 16 human tissues (Figure 1,
Neth et al., 2001). Therefore, it was expected that the
PPK protein is synthesised in various tissues. However,
studies on the localisation of the protein are scarce.
Besides Cerf et al. (1999) and Cerf and Raidoo (2000) (cf.
the results section), Hermann et al. (1996) localised PPK/
PK on the endothelial cells of villous capillaries of human
term placenta, but the authors suggested that endothelial
cells may adsorb the protein from foetal blood. Thus,
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Figure 4 Immunoreactive PPK/PK expression in endocrine cells of Langerhans islets of human pancreas (A, B), follicular granulosa
cells (C, D), and Leydig cells (E, F).
Arrows indicate nuclear localisation of the enzyme in follicular granulosa cells (D) and in Leydig cells (F). LC, Leydig cells. Scale bars:
(A,D,E) 100 mm; (C) 200 mm; (B,F) 50 mm.
whereas PPK gene transcription in non-hepatic tissues
is now well documented, the question addressed here
was whether PPK mRNA could evoke expression of the
zymogen protein. In essence and most importantly, a
wide variety of progenitor-derived cells showed the
capacity to synthesise the enzyme, as evidenced from
our immunolabelling experiments. Although no quantita-
tive comparison of PPK mRNA expression and PPK/PK
protein content in the tissues is possible from the present
study, it is interesting to note that significant immuno-
reactivity to PPK/PK was detected in tissues expressing
very low levels of PPK mRNA, such as lung and ovary.
The possibility that the immunolocalised PK/PPK rep-
resents enzyme non-specifically adsorbed from the
blood plasma can be ruled out, since in that case label-
ling of all cells of a tissue and not only of defined cell
types would be expected. A second possibility, namely
that PPK is – despite the cellular expression of its mRNA
– not synthesised, but selectively internalised by defined
cells, is improbable.
The next question to address is the physiological
importance of the almost universal occurrence of the
enzyme in the cytoplasm and on the nuclear envelope of
immunoreactive cells. It is reasonable to assume that the
PPK synthesised in these cells may subserve special
local functions at or near the cellular site of its synthesis.
Recently, a novel function of PK was described that pro-
vides experimental evidence of direct activation of the
kinin B2 receptor, independent of kinin release (Hecquet
et al., 2000, 2002; Biyashev et al., 2006). The proteolytic
activity of PK is compulsory for this receptor activation,
but the mechanism of action seems to be different from
that of the known proteinase-activated receptors (Dery et
al., 1998). Unlike tissue kallikrein hK1, PPK appears to
be mainly expressed as a non-granular protein, sugges-
tive of an intracrine function. On the other hand, it may
be postulated that the proteolytic regulation of adipoge-
nesis (Selvarajan et al., 2001), the activation of pro-hepa-
tocyte growth factor (Peek et al., 2002) and the latent
form of transforming growth factor (Akita et al., 2002) are
functions of PPK/PK that resides in the endoplasmic
reticulum of particular cells. The novel finding of PPK/PK
on the nuclear membrane provides new evidence of the
participation of PK in regulating mechanisms at this site.
In our study we demonstrated that PPK/PK is indeed
detectable in cells of a variety of embryologically derived
cells, giving credence to the concept that PK may mod-
ulate specialised cytoplasmic and nuclear functions of
many human cells.
Materials and methods
Ethical permission
Ethical permission for the study was obtained from the Ethics
Committee of the University of Natal Medical School, Durban,
South Africa.
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Tissue collection and processing
Surgical and autopsy samples were collected from different
embryologically derived human tissues: (1) metanephric blaste-
ma-derived renal tissue; (2) endodermal/ectodermal tissues
including liver, parotid glands, lung and bronchi, oesophagus,
breast, prostate and skin; and (3) endocrine tissue consisting of
pancreas, ovary and testes. Post-mortem samples were col-
lected within 24 h of death and were obtained from individual
corpses who had been immediately refrigerated and maintained
at 48C. The specimens were fixed in 5% formalin saline for 24 h
at room temperature and paraffin-embedded using conventional
procedures. In addition, arrays of adult human tissues were pur-
chased from BioCat (Heidelberg, Germany). These slides were
pre-treated according to the manufacturer’s instructions.
Antibodies
To optimise the antibody dilution for immunohistochemistry, as
a first step all antibodies were diluted within the range 1:50 to
1:300. In this study five different antibody preparations were
used. (i) A polyclonal antiserum AS176 against human PPK was
raised in New Zealand white rabbits. The lyophilised whole anti-
serum was reconstituted in deionised water and used at a dilu-
tion of 1:400 in phosphate-buffered saline (PBS). (ii) Murine
monoclonal antibodies PK7 and PK11 are directed against the
human PPK heavy and light chains, respectively. Lyophilised
ascites fluid was reconstituted in deionised water and used at
dilutions of 1:150 and 1:450, respectively, in PBS. The prepa-
ration and characterisation of these antibodies has been
described previously (Hock et al., 1990; Herwald et al., 1993).
These three antibodies were generous gifts of Prof. W. Mu¨ller-
Esterl, Johann Wolfgang Goethe-University, Frankfurt, Germany.
(iii) A rabbit antiserum to human PPK was kindly provided by
Prof. B.N. Bouma, Utrecht University, The Netherlands. The IgG
was isolated by affinity chromatography on ProteinG-Sepharose
(Pharmacia, Uppsala, Sweden). Since immunoblotting showed
that the preparation contained antibodies against human IgG,
the antibody was additionally passed through a human IgG-
Sepharose column. Fractions of the flow-through containing IgG
not adsorbed onto the column (PK427.10) were collected and
lyophilised. Western blot experiments with PK427.10 demon-
strated that the antibodies reacting with human IgG had been
removed successfully, since the signal obtained with 0.2 mg of
PK or PPK was stronger than that of 375 nl of human plasma
(approx. 6 mg of IgG). Furthermore, immunoreactivity of this and
the other antibodies was compared on human kidney sections
with that observed using an anti-human IgG antibody purchased
from Dako (Carpinteria, CA, USA). This antibody was used at a
dilution of 1:50 in PBS. (iv) Antiserum U691.10 to the peptide
CTTKTSTR, representing the C-terminal end of the PK heavy
chain, was raised in rabbits by a commercial service (Eurogen-
tec, Lie`ge, Belgium). The IgG was isolated from the anti-
serum by affinity chromatography on a Protein A-Sepharose
column. The IgG-containing fractions were pooled and lyophil-
ised. The antibody preparation was used at a dilution of 1:50.
U691.10 should be specific for active PK. Unexpectedly, in
Western blot experiments antibody U691.10 also detected
human IgG. This cross-reactivity with human IgG is presumably
caused by a sequence similarity, since a BLAST search found
five sequences of human IgG heavy chains with sequencemotifs
with 50% or 63% identity with the peptide used for immunisa-
tion wCTxxTS, TTxTST, TTxxSTR (ns2) and CTTxxSTx. In fact, in
a Western blot experiment with reduced human IgG a weak sin-
gle band of 50 kDa was detected, obviously representing the
heavy chain of IgG.
All five antibodies were equally well suited for detecting PPK/
PK in human tissue sections.
Immunohistochemistry
Paraffin-embedded sections were dewaxed with xylene and
rehydrated through a graded series of ethanol and finally in dis-
tilled water. Antigen retrieval was performed by boiling the slides
in 0.1 M sodium citrate, pH 6.0 in a microwave oven (Sharp R-
4A52, Mahway, NJ, USA) at high power for 3 min, at low power
for 5 min and finally allowing them to cool at room temperature
for 20 min. Endogenous pseudoperoxidase activity was inacti-
vated by incubating the sections with 5% H2O2 in absolute
methanol for 30 min. Non-specific binding sites were masked
by incubating the sections with non-immune serum for 30 min
at room temperature. The sections were then probed for the
presence of immunoreactive PPK/PK with the antibodies men-
tioned above. After overnight incubation with the primary anti-
body at 48C, the sections were thoroughly washed and
incubated with the biotinylated secondary anti-species antibody,
followed by the streptavidin-peroxidase complex (Dako). The
enzyme-substrate reaction was detected using diaminobenzi-
dine. After immunostaining, tissue sections were lightly coun-
terstained with Harris haematoxylin, dehydrated and mounted in
DPX, and visualised using a Nikon light microscope. To assess
the specificity of the immunolabelling method, controls were
prepared in which the primary antibody solution was replaced
by PBS, non-immune serum, or a solution of the primary anti-
body preabsorbed by PPK.
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